Electrocardiographic left ventricular (LV) hypertrophy involving ST-T abnormalities, in addition to high QRS voltages, is associated with increased risk of cardiovascular disease mortality. Unfortunately, conventional electrocardiographic criteria have limited utility in the quantitative assessment of LV hypertrophy. Body surface potential maps, which contain diagnostic information not present in commonly used lead systems, were recorded from 117 thoracic sites and 3 limb electrodes in 72 normal subjects and 84 patients with LV hypertrophy. Multiple regression analysis was performed separately for 54 women and 102 men on 120-lead data, using as features instantaneous voltages on time-normalized P, PR, QRS and ST-T waveforms. Leads and features for optimal prediction of echocardiographically determined LV mass were selected. A total of 6 features from 3 torso sites in men, and from the same 3 sites plus 2 others in women, yielded correlations between echocardiographic and electrocardiographic estimates of LV mass of 0.89 and 0.88, respectively. The standard errors of the estimate (SEE), or average errors in predicting LV mass from the regression equations, were 31 and 22 g, respectively. The single most potent predictor in both sexes was a mid-QRS voltage measured on a lead positioned 10 cm below V1; QRS duration, late QRS and early-to-mid T-wave amplitudes recorded in the lower left flank contributed significantly to the performance of both regression models. The optimal electrode sites for electrocardiographic prediction of LV mass were outside the conventional lead locations.(ABSTRACT TRUNCATED AT 250 WORDS)

Download full-text PDF

Source
http://dx.doi.org/10.1016/0002-9149(90)90710-iDOI Listing

Publication Analysis

Top Keywords

left ventricular
8
mass regression
8
regression analysis
8
body surface
8
surface potential
8
potential maps
8
mass
5
improved prediction
4
prediction left
4
ventricular mass
4

Similar Publications

The ratio of serum acylcarnitines to free carnitines (AC/FC) reflects impaired cardiomyocyte β-oxidization. The effect of heart failure (HF) treatment on AC/FC remained unclear. This pilot study retrospectively examined treatment-induced AC/FC changes in patients with HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF) in 148 consecutive inpatients undergoing echocardiography and carnitine measurement at admission and discharge.

View Article and Find Full Text PDF

This study aims to develop a nomogram prediction model for assessing the cardiogenic composite endpoint, which includes intracardiac thrombosis (ICT) combined with heart failure (HF) in patients with non-compaction cardiomyopathy (NCM) patients. We retrospectively analyzed clinical data from NCM patients (January 2018 to May 2024), who were randomly assigned to training and validation cohorts. Independent predictors were identified using logistic regression, and a nomogram model was developed.

View Article and Find Full Text PDF

We investigated the impact of trimetazidine treatment on left ventricular (LV) functions and cardiac biomarkers in diabetic patients with diastolic dysfunction as an early stage of diabetic cardiomyopathy. Sixty-three patients were randomly assigned to receive either trimetazidine or a placebo for 3 months. At baseline and after 3-months of treatment, measurements of serum levels of glycemic control parameters, lipid profile, tumor necrosis factor alpha, transforming growth factor beta 1, n-terminal pro brain natriuretic peptide and assessment of modified Medical Research Council (mMRC) dyspnea score, echocardiographic indices of LV functions and LV global longitudinal strain (GLS) were performed.

View Article and Find Full Text PDF

A novel wearable device integrating ECG and PCG for cardiac health monitoring.

Microsyst Nanoeng

January 2025

Key Laboratory of Instrumentation Science and Dynamic Measurement Ministry of Education, North University of China, 030051, Taiyuan, China.

The alarming prevalence and mortality rates associated with cardiovascular diseases have emphasized the urgency for innovative detection solutions. Traditional methods, often costly, bulky, and prone to subjectivity, fall short of meeting the need for daily monitoring. Digital and portable wearable monitoring devices have emerged as a promising research frontier.

View Article and Find Full Text PDF

Background: An initial decline in estimated glomerular filtration rate (eGFR) often leads to reluctance to continue life-saving therapies in patients with heart failure (HF).

Objectives: The goal of this study was to describe the association between initial decline in eGFR and subsequent clinical outcomes in patients randomized to placebo or finerenone.

Methods: In this prespecified analysis of FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure), we examined the association between initial decline in eGFR (≥15%) from randomization to 1 month and subsequent outcomes in patients assigned to finerenone or placebo.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!